Head to Head Contrast: NewAmsterdam Pharma (NASDAQ:NAMS) and INmune Bio (NASDAQ:INMB)

NewAmsterdam Pharma (NASDAQ:NAMS) and INmune Bio (NASDAQ:INMB) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

Insider and Institutional Ownership

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 21.4% of INmune Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares NewAmsterdam Pharma and INmune Bio”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50 million	106.58	-$203.82 million	($2.16)	-9.29
INmune Bio	$50,000.00	804.75	-$45.93 million	($0.67)	-2.16

INmune Bio has lower revenue, but higher earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for NewAmsterdam Pharma and INmune Bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1	1	9	1	2.83
INmune Bio	1	0	0	1	2.50

NewAmsterdam Pharma presently has a consensus target price of $48.90, suggesting a potential upside of 143.77%. Given NewAmsterdam Pharma’s stronger consensus rating and higher probable upside, equities research analysts clearly believe NewAmsterdam Pharma is more favorable than INmune Bio.

Profitability

This table compares NewAmsterdam Pharma and INmune Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%
INmune Bio	N/A	-82.87%	-62.23%

Volatility & Risk

NewAmsterdam Pharma has a beta of 0.1, indicating that its share price is 90% less volatile than the S&P 500. Comparatively, INmune Bio has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

About INmune Bio

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.